Status:

TERMINATED

Study Evaluating Metabolic Syndrome in Subjects Undergoing Gastric Bypass Bariatric Syndrome

Lead Sponsor:

Wyeth is now a wholly owned subsidiary of Pfizer

Conditions:

Morbid Obesity

Metabolic Disease

Eligibility:

All Genders

18-55 years

Brief Summary

Metabolic syndrome is rapidly emerging as an epidemic of global proportions and its definition is still evolving. Patients with this syndrome are at increased risk for cardiovascular disease, and at i...

Eligibility Criteria

Inclusion

  • All subjects must be approved by both insurance and site standard of care to undergo the Roux-en-Y gastric bypass procedure
  • Male and Female Candidates for Roux-en-Y Bariatric Surgery
  • Must be diagnosed with Metabolic Syndrome; having abdominal obesity and at least 2 other features of the syndrome per IDF (International Diabetes Foundation)
  • Obese control group:Subjects should be obese and should not have any other features of metabolic syndrome.

Exclusion

  • Any subjects with prior bariatric surgery
  • No other major surgery within the last 6 months
  • Diabetes on treatment with hypoglycemic medication in the previous 6 months
  • Other exclusions apply

Key Trial Info

Start Date :

October 1 2005

Trial Type :

OBSERVATIONAL

End Date :

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT00283374

Start Date

October 1 2005

Last Update

May 18 2006

Active Locations (17)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (17 locations)

1

Irvine, California, United States, 92697-1050

2

Orange, California, United States, 92868

3

Atlanta, Georgia, United States, 30322

4

Indianapolis, Indiana, United States, 46278